CSL Behring to acquire global license rights to adeno-associated virus gene therapy program, AMT 061 for hemophilia B from uniQure.
CSL Behring announced that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT 061 (etranacogene dezaparvovec), for the… read more.